Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) will be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Allogene Therapeutics to post earnings of ($0.34) per share for the quarter.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Allogene Therapeutics Stock Down 3.0 %
Shares of ALLO traded down $0.08 during mid-day trading on Thursday, hitting $2.56. 2,207,924 shares of the company's stock were exchanged, compared to its average volume of 2,451,520. The firm has a fifty day moving average of $2.69 and a two-hundred day moving average of $2.69. Allogene Therapeutics has a twelve month low of $2.01 and a twelve month high of $5.78. The stock has a market cap of $535.33 million, a price-to-earnings ratio of -1.61 and a beta of 0.83.
Analysts Set New Price Targets
Several research analysts have recently commented on ALLO shares. Truist Financial restated a "buy" rating and set a $14.00 price target (down previously from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Oppenheimer assumed coverage on shares of Allogene Therapeutics in a research note on Thursday, August 8th. They issued an "outperform" rating and a $11.00 target price on the stock. Canaccord Genuity Group lowered their target price on shares of Allogene Therapeutics from $35.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, August 8th. Citigroup raised their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Allogene Therapeutics in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $9.96.
Check Out Our Latest Research Report on ALLO
Allogene Therapeutics Company Profile
(
Get Free Report)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Read More
Before you consider Allogene Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.
While Allogene Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
